BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND PER1, O15534, 5187, ENSG00000179094, RIGUI
22 results:

  • 1. Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.
    Marrone MT; Prizment AE; Couper D; Butler KR; Astor BC; Joshu CE; Platz EA; Mondul AM
    Prostate; 2023 Aug; 83(11):1046-1059. PubMed ID: 37154584
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. "Time" for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment.
    Miro C; Docimo A; Barrea L; Verde L; Cernea S; Sojat AS; Marina LV; Docimo G; Colao A; Dentice M; Muscogiuri G
    Semin Cancer Biol; 2023 Jun; 91():99-109. PubMed ID: 36893964
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in prostate cancer.
    Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
    Front Immunol; 2022; 13():777724. PubMed ID: 35154101
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The deleterious association between proton pump inhibitors and prostate cancer-specific mortality - a population-based cohort study.
    Goldberg H; Mohsin FK; Saskin R; Kulkarni GS; Berlin A; Kenk M; Wallis CJD; Chandrasekar T; Klaassen Z; Saarela O; Penn L; Alibhai SMH; Fleshner N
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):622-629. PubMed ID: 32641738
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Patterns of treatment failure in patients with prostate cancer treated with 76-80 Gy radiotherapy to the prostate and seminal vesicles ± hormonotherapy.
    López-Torrecilla J; Pastor-Peidro J; Vicedo-González A; González-Sanchis D; Hernandez-Machancoses A; Almendros-Blanco P; García-Miragall E; Gordo-Partearroyo JC; García-Hernández T; Brualla-González L; Granero-Cabañero D; Rosello-Ferrando J
    Clin Transl Oncol; 2021 Mar; 23(3):481-490. PubMed ID: 32621208
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Optimising Radium 223 Therapy for Metastatic Castration-Resistant prostate cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
    Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
    Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clock genes and cancer development in particular in endocrine tissues.
    Angelousi A; Kassi E; Ansari-Nasiri N; Randeva H; Kaltsas G; Chrousos G
    Endocr Relat Cancer; 2019 Jun; 26(6):R305-R317. PubMed ID: 30959483
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Circadian genes and risk of prostate cancer: Findings from the EPICAP study.
    Wendeu-Foyet MG; Koudou Y; Cénée S; Trétarre B; Rébillard X; Cancel-Tassin G; Cussenot O; Boland A; Bacq D; Deleuze JF; Lamy PJ; Mulot C; Laurent-Puig P; Truong T; Menegaux F
    Int J Cancer; 2019 Oct; 145(7):1745-1753. PubMed ID: 30665264
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies.
    Mocellin S; Tropea S; Benna C; Rossi CR
    BMC Med; 2018 Feb; 16(1):20. PubMed ID: 29455641
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. WOMEN IN cancer THEMATIC REVIEW: Circadian rhythmicity and the influence of 'clock' genes on prostate cancer.
    Kiss Z; Ghosh PM
    Endocr Relat Cancer; 2016 Nov; 23(11):T123-T134. PubMed ID: 27660402
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
    Grenader T; Plotkin Y; Rosengarten O
    Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Image-guided radiation therapy based on helical tomotherapy in prostate cancer: minimizing toxicity.
    Acevedo-Henao CM; Lopez Guerra JL; Matute R; Puebla F; Russo M; Rivin E; Sanchez-Reyes A; Ortiz MJ; Azinovic I
    Oncol Res Treat; 2014; 37(6):324-30. PubMed ID: 24903763
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.
    Mohile SG; Lacy M; Rodin M; Bylow K; Dale W; Meager MR; Stadler WM
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):152-9. PubMed ID: 20656210
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Efficacy and safety of single-session argon plasma coagulation in the management of chronic radiation proctitis.
    Swan MP; Moore GT; Sievert W; Devonshire DA
    Gastrointest Endosc; 2010 Jul; 72(1):150-4. PubMed ID: 20493484
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.
    Zhu Y; Stevens RG; Hoffman AE; Fitzgerald LM; Kwon EM; Ostrander EA; Davis S; Zheng T; Stanford JL
    Cancer Res; 2009 Dec; 69(24):9315-22. PubMed ID: 19934327
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A role for the clock gene per1 in prostate cancer.
    Cao Q; Gery S; Dashti A; Yin D; Zhou Y; Gu J; Koeffler HP
    Cancer Res; 2009 Oct; 69(19):7619-25. PubMed ID: 19752089
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I.
    Chu LW; Zhu Y; Yu K; Zheng T; Chokkalingam AP; Stanczyk FZ; Gao YT; Hsing AW
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3268-73. PubMed ID: 18990770
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Variants in circadian genes and prostate cancer risk: a population-based study in China.
    Chu LW; Zhu Y; Yu K; Zheng T; Yu H; Zhang Y; Sesterhenn I; Chokkalingam AP; Danforth KN; Shen MC; Stanczyk FZ; Gao YT; Hsing AW
    Prostate Cancer Prostatic Dis; 2008; 11(4):342-8. PubMed ID: 17984998
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b.
    Masue N; Deguchi T; Nakano M; Ehara H; Uno H; Takahashi Y
    Int J Urol; 2005 Dec; 12(12):1045-9. PubMed ID: 16409608
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.